Bajorin DF - Search Results

1

Witjes JA, Galsky MD, Gschwend JE, Broughton E, Braverman J, Nasroulah F, Maira-Arce M, Ye X, Shi L, Guo S, Hamilton M, Bajorin DF. Witjes JA, et al. Among authors: bajorin df. Eur Urol Oncol. 2022 Oct;5(5):553-563. doi: 10.1016/j.euo.2022.02.003. Epub 2022 Mar 11. Eur Urol Oncol. 2022. PMID: 35288066 Free PMC article. Clinical Trial.

2

Methotrexate, vinblastine, doxorubicin and cisplatin chemotherapy and cystectomy for unresectable bladder cancer.

Donat SM, Herr HW, Bajorin DF, Fair WR, Sogani PC, Russo P, Sheinfeld J, Scher I. Donat SM, et al. Among authors: bajorin df. J Urol. 1996 Aug;156(2 Pt 1):368-71. doi: 10.1097/00005392-199608000-00009. J Urol. 1996. PMID: 8683681 Clinical Trial.

3

Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma.

McCaffrey JA, Hilton S, Mazumdar M, Sadan S, Kelly WK, Scher HI, Bajorin DF. McCaffrey JA, et al. Among authors: bajorin df. J Clin Oncol. 1997 May;15(5):1853-7. doi: 10.1200/JCO.1997.15.5.1853. J Clin Oncol. 1997. PMID: 9164195 Clinical Trial.

4

Phase II randomized trial of gallium nitrate plus fluorouracil versus methotrexate, vinblastine, doxorubicin, and cisplatin in patients with advanced transitional-cell carcinoma.

McCaffrey JA, Hilton S, Mazumdar M, Sadan S, Heineman M, Hirsch J, Kelly WK, Scher HI, Bajorin DF. McCaffrey JA, et al. Among authors: bajorin df. J Clin Oncol. 1997 Jun;15(6):2449-55. doi: 10.1200/JCO.1997.15.6.2449. J Clin Oncol. 1997. PMID: 9196161 Clinical Trial.

5

Treatment of patients with transitional-cell carcinoma of the urothelial tract with ifosfamide, paclitaxel, and cisplatin: a phase II trial.

Bajorin DF, McCaffrey JA, Hilton S, Mazumdar M, Kelly WK, Scher HI, Spicer J, Herr H, Higgins G. Bajorin DF, et al. J Clin Oncol. 1998 Aug;16(8):2722-7. doi: 10.1200/JCO.1998.16.8.2722. J Clin Oncol. 1998. PMID: 9704723 Clinical Trial.

6

Can p53 help select patients with invasive bladder cancer for bladder preservation?

Herr HW, Bajorin DF, Scher HI, Cordon-Cardo C, Reuter VE. Herr HW, et al. Among authors: bajorin df. J Urol. 1999 Jan;161(1):20-2; discussion 22-3. J Urol. 1999. PMID: 10037358

7

Paclitaxel in the treatment of advanced urothelial cancer.

Bajorin DF. Bajorin DF. Oncology (Williston Park). 2000 Jan;14(1):43-52, 57; discussion 58, 61-2. Oncology (Williston Park). 2000. PMID: 10680149 Review.

8

Phase II trial of pyrazoloacridine as second-line therapy for patients with unresectable or metastatic transitional cell carcinoma.

Dodd PM, McCaffrey JA, Mazumdar M, Icasiano E, Higgins G, Herr H, Bajorin DF. Dodd PM, et al. Among authors: bajorin df. Invest New Drugs. 2000 Aug;18(3):247-51. doi: 10.1023/a:1006477823378. Invest New Drugs. 2000. PMID: 10958593 Clinical Trial.

9

Post-chemotherapy surgery in patients with unresectable or regionally metastatic bladder cancer.

Herr HW, Donat SM, Bajorin DF. Herr HW, et al. Among authors: bajorin df. J Urol. 2001 Mar;165(3):811-4. J Urol. 2001. PMID: 11176475

10

Impact of the number of lymph nodes retrieved on outcome in patients with muscle invasive bladder cancer.

Herr HW, Bochner BH, Dalbagni G, Donat SM, Reuter VE, Bajorin DF. Herr HW, et al. Among authors: bajorin df. J Urol. 2002 Mar;167(3):1295-8. J Urol. 2002. PMID: 11832716

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

290 results

Search Page

Filters